Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Co. (UK) Ltd. as Sole Book-Running Manager of Viking Therapeutics’ $24.0M IPO
New York, NY – May 6, 2015 – New York City based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (the “Firm”) announced today that the Firm has represented Laidlaw & CO. (UK) Ltd. as the sole book-running manager of the initial public offering (IPO) of Viking Therapeutics, Inc. (NASDAQ: VKTX). The public offering consisted of 3,000,000 shares of the Company’s common stock at a price to the public of $8.00 per share which resulted in aggregate gross proceeds of $24,000,000 before deducting expenses. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The Sichenzia Ross Friedman Ference LLP team was led by Partners Richard A. Friedman and Stephen A. Cohen.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference Represents Pareteum Corporation in Tender Offer for Shares of iPass, Inc. and Completes Acquisition - February 14, 2019
- Sichenzia Ross Ference Partner Ralph Preite Participates on Financial Poise’s “Legal Ethics – Best Practices” Webinar - February 14, 2019
- Sichenzia Ross Ference LLP Adds Jeff D’Angelo as Corporate & Securities Partner - February 13, 2019